Abstract
Purpose
Proliferation activity has long been known to be one of the strongest prognostic factors in many different cancers. Nevertheless, microscopic evaluation of mitotic figures remains time-consuming and, furthermore, is relatively subjective. As the expression of cytoskeleton-associated protein 2 (CKAP2) is closely related to the mitotic phase, CKAP2 was evaluated as a surrogate mitotic figure (MF) marker.
Methods
A monoclonal antibody specific to human CKAP2 was produced, and immunohistochemistry was performed on normal tissue array sections and 30 breast cancer tissues.
Results
The expression of CKAP2 in the normal human tissues was limited to well-known cell proliferation zones. Strong, readily visible, condensed chromatin staining of CKAP2 was observed specifically in mitotic cells, and the number of these cells was tightly correlated with the MF count in breast cancer tissues (P < 0.001, ρ = 0.743), suggesting its usefulness as a surrogate marker for MF counting.
Conclusion
Immunohistochemical staining with CKAP2 monoclonal antibody can be considered to be a new, effective approach to the assessment of proliferation activity in cancer tissues.
Similar content being viewed by others
Abbreviations
- CKAP2:
-
Cytoskeleton-associated protein 2
- MF:
-
Mitotic figure
- FFPE:
-
Formalin-fixed paraffin-embedded
References
Amadori D, Nanni O, Marangolo M, Pacini P, Ravaioli A, Rossi A, Gambi A, Catalano G, Perroni D, Scarpi E, Giunchi DC, Tienghi A, Becciolini A, Volpi A (2000) Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. J Clin Oncol 18(17):3125–3134
Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB, Janssen EA (2005) Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 23(25):5993–6001. doi:10.1200/JCO.2005.05.511
Baak JP, Gudlaugsson E, Skaland I, Guo LH, Klos J, Lende TH, Soiland H, Janssen EA, Zur Hausen A (2009) Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat 115(2):241–254. doi:10.1007/s10549-008-0126-y
Bae CD, Sung YS, Jeon SM, Suh Y, Yang HK, Kim YI, Park KH, Choi J, Ahn G, Park J (2003) Up-regulation of cytoskeletal-associated protein 2 in primary human gastric adenocarcinomas. J Cancer Res Clin Oncol 129(11):621–630. doi:10.1007/s00432-003-0484-0
Chibon F, Lagarde P, Salas S, Perot G, Brouste V, Tirode F, Lucchesi C, de Reynies A, Kauffmann A, Bui B, Terrier P, Bonvalot S, Le Cesne A, Vince-Ranchere D, Blay JY, Collin F, Guillou L, Leroux A, Coindre JM, Aurias A (2010) Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 16(7):781–787. doi:10.1038/nm.2174
Eichmuller S, Usener D, Dummer R, Stein A, Thiel D, Schadendorf D (2001) Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci USA 98(2):629–634. doi:10.1073/pnas.021386498
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921. doi:10.1038/nature03445
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123–134. doi:10.1056/NEJMoa0900212
Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P, Guerry D (2005) Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 23(31):8048–8056. doi:10.1200/JCO.2005.02.0735
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312. doi:10.1200/JCO.2007.14.2364
Hong KU, Park YS, Seong YS, Kang D, Bae CD, Park J (2007) Functional importance of the anaphase-promoting complex-Cdh1-mediated degradation of TMAP/CKAP2 in regulation of spindle function and cytokinesis. Mol Cell Biol 27(10):3667–3681. doi:10.1128/MCB.01386-06
Hong KU, Choi YB, Lee JH, Kim HJ, Kwon HR, Seong YS, Kim HT, Park J, Bae CD, Hong KM (2008) Transient phosphorylation of tumor associated microtubule associated protein (TMAP)/cytoskeleton associated protein 2 (CKAP2) at Thr-596 during early phases of mitosis. Exp Mol Med 40(4):377–386
Hong KU, Kim HJ, Bae CD, Park J (2009a) Characterization of mitosis-specific phosphorylation of tumor-associated microtubule-associated protein. Exp Mol Med 41(11):832–840. doi:10.3858/emm.2009.41.11.089
Hong KU, Kim HJ, Kim HS, Seong YS, Hong KM, Bae CD, Park J (2009b) Cdk1-cyclin B1-mediated phosphorylation of tumor-associated microtubule-associated protein/cytoskeleton-associated protein 2 in mitosis. J Biol Chem 284(24):16501–16512. doi:10.1074/jbc.M900257200
Hsu CY, Ho DM, Yang CF, Chiang H (2003) Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods. Mod Pathol 16:951–957
Jeon SM, Choi B, Hong KU, Kim E, Seong YS, Bae CD, Park J (2006) A cytoskeleton-associated protein, TMAP/CKAP2, is involved in the proliferation of human foreskin fibroblasts. Biochem Biophys Res Commun 348(1):222–228. doi:10.1016/j.bbrc.2006.07.046
Jin Y, Murakumo Y, Ueno K, Hashimoto M, Watanabe T, Shimoyama Y, Ichihara M, Takahashi M (2004) Identification of a mouse cytoskeleton-associated protein, CKAP2, with microtubule-stabilizing properties. Cancer Sci 95(10):815–821
Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ (2011) Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 13(2):R22. doi:10.1186/bcr2834
Kulkarni MB, Desai SB, Ajit D, Chinoy RF (2009) Utility of the thromboplastin-plasma cell-block technique for fine-needle aspiration and serous effusions. Diagn Cytopathol 37(2):86–90. doi:10.1002/dc.20963
Maouche-Chretien L, Deleu N, Badoual C, Fraissignes P, Berger R, Gaulard P, Romeo PH, Leroy-Viard K (1998) Identification of a novel cDNA, encoding a cytoskeletal associated protein, differentially expressed in diffuse large B cell lymphomas. Oncogene 17(10):1245–1251. doi:10.1038/sj.onc.1202048
Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L, Daniels TR, Penichet ML, Feldman R, Lichtenstein A (2007) Targeting aurora kinases as therapy in multiple myeloma. Blood 109(9):3915–3921. doi:10.1182/blood-2006-07-037671
Valera V, Yokoyama N, Walter B, Okamoto H, Suda T, Hatakeyama K (2005) Clinical significance of Ki-67 proliferation index in disease progression and prognosis of patients with resected colorectal carcinoma. Br J Surg 92(8):1002–1007. doi:10.1002/bjs.4858
van Diest PJ, Baak JP, Matze-Cok P, Wisse-Brekelmans EC, van Galen CM, Kurver PH, Bellot SM, Fijnheer J, van Gorp LH, Kwee WS et al (1992) Reproducibility of mitosis counting in 2, 469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 23(6):603–607
Velders GA, Kluin-Nelemans JC, De Boer CJ, Hermans J, Noordijk EM, Schuuring E, Kramer MH, Van Deijk WA, Rahder JB, Kluin PM, Van Krieken JH (1996) Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol 14(4):1269–1274
Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, Matese JC, Perou CM, Hurt MM, Brown PO, Botstein D (2002) Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13(6):1977–2000. doi:10.1091/mbc.02-02-0030
Acknowledgments
This work was supported by research grants (nos. 0810240 and 1110130) from the National Cancer Center, Korea, to K.M.H., by grants from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Korea, (no. 0720370) and from Samsung Biomedical Research Institute, Korea (no. BB01022), to C.D.B., and by a grant (2011) from Inje University, Korea, to H.S.K.
Conflict of interest
We declare that we have no conflict of interest.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Kim, HS., Choi, YB., Lee, JH. et al. Condensed chromatin staining of CKAP2 as surrogate marker for mitotic figures. J Cancer Res Clin Oncol 138, 95–102 (2012). https://doi.org/10.1007/s00432-011-1053-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-011-1053-6